|[April 03, 2014]
Bioprinting Investment Puts RBCC at Forefront of 3-D Revolution
MIRAMAR BEACH, Fla. --(Business Wire)--
By substantially increasing its investment in biotech innovators Nano3D
Biosciences, Rainbow Coral Corp. (OTCBB: RBCC) has positioned itself on
the front lines of a bioprinting revolution poised to forever alter the
possibilities of healthcare.
Nano 3D Biosciences (n3D) is a cutting-edge technology company drawing
international interest with its revolutionary BiO Assay, the first
commercially available 3D bioprinting system designed for high
throughput and high-content drug screening. The automated toxicity assay
uses biocompatible magnetic nanoparticles to print cells into 3D
structures much faster and more affordably than competing bioprinting
technology currently on the market.
RBCC took an equity interest in n3D in 2012, not long after the
companies formed a joint venture to market and develop new technologies
for the fast-growing, global biotechnology marketplace. With a new
investment agreement now in place, RBCC could be positioned for major
growth as n3D becomes a leading stakeholder in an industry forecast to
be worth $10 billion by 2030.
"The BiO Assay is the only system of its kind that is commercially
available in the global bioprinting industry," said RBCC CEO Kimberly
Palmer. "It's one of the most important pieces of technology to emerge
n the past decade, and we're fully committed to its global
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and
develop new medical and research technology innovations to compete
alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott
Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow
Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To TMCnet.com's Homepage ]